Disitamab Vedotin With Pembrolizumab Versus Chemotherapy for la/mUC Expressing HER2

Matthew Galsky, MD, of Icahn School of Medicine at Mount Sinai, and Amanda Nizam, MD, of Cleveland Clinic, continue their conversation with a spotlight on a phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2.

View their previous comments on CheckMate 901: Characterizing Complete Responders, Patients With Lymph Node-Only mUC.